McCabe Noonan (dreamart28)

Backround Urotensin-2 (U-II), which is one of the most effective known vasoconstrictor peptides, was observed to act as a vasoconstrictor in diseases such as hypertension and heart failure, and to induce vasodilation in healthy volunteers. Some studies have proposed that the activation of the U-II system could lead to metabolic syndrome. WZ811 purchase Certain studies have determined a link between Diabetes Mellitus and U-II. However, there exist no studies on the effects of U-II in recently diagnosed Type 2 DM patients after metformin treatment. OBJECTIVE This study aims to investigate the plasma and saliva levels of U-II at diagnosis and after 3-month metformin treatment in recently diagnosed Type 2 DM patients and compare these levels to those of healthy volunteers. METHODS Our study compared 30 recently diagnosed Type 2 DM patients to their states after 3-month metformin treatment and 30 healthy volunteers. RESULTS When compared with the control group, there was no significant increase in the plasma and saliva U-II levels of recently diagnosed Type 2 DM patients. We determined a statistically significant increase in the plasma and saliva ureotensin-2 levels of recently diagnosed Type 2 DM patients after 3-month metformin treatment (p less then 0.05). CONCLUSIONS It is concluded that , the patients with Type 2 DM, have a multifactorial ethiopathogenesis, U-II levels increase after metformin treatment. Metformin has no known effect on the U-II metabolism. therefore the findindings need confirmation through more clinical and experimental studies that will include more participants.BACKGROUND Graves disease (GD) as a consequence of radioactive iodine (RAI) therapy is rare, usually presenting as post-therapeutic-RAI immunogenic hyperthyroidism. The present study describes a patient with a thyroid remnant after surgery and no metastases of papillary thyroid cancer who was treated with low activity RAI. Her RAI-induced GD manifested clinically as Graves orbitopathy (GO), and she had high levels of antibodies to thyroid stimulating hormone receptor (TRAb). CASE PRESENTATION A 49-year-old woman with a history of non-toxic nodular goiter was referred for postoperative evaluation after total thyroidectomy for papillary thyroid microcarcinoma. Physical examination revealed no ocular symptoms, and ultrasound of the neck revealed no focal lesions in the thyroid bed. Immunoassays showed normal levels of TRAb and anti-thyroglobulin antibodies, and elevated levels of thyroid peroxidase antibodies (TPOAb). A diagnostic whole body scan (WBS) showed negligible uptake of iodine on the left side of the thyroid bed. Three months later, the patient developed clinically significant orbitopathy and her TRAb level was elevated. She was started on methylprednisolone therapy while tapering doses. Four months later, her TRAb had decreased and she showed clinical improvements in ocular symptoms and signs. CONCLUSIONS To our knowledge, this is the first case report describing GD/GO induced by a low activity RAI and the presence of a thyroid remnant after total thyroidectomy. RAI-induced GD/GO should be considered in the differential diagnosis of TPO-positive patients, even if their thyroids had been removed.Papillary carcinoma is the most frequently occurring thyroid cancer among both children and adults which may occur at any age. Exposition to the ionizing radiation is the main risk factor. Papillary carcinoma may be indicated by the painless tumor, which is hormonally inactive. The long-term survival rate is dependent upon patient's age, infiltration of the surrounding tissues and remote metastases. The carcinoma sites may include fibrosis areas, psammoma bodies, squamous metaplasia features. The osseous metaplasia tumor is a rare occurrence. This study reports the case of the patient who underwent thyroidectomy, diagnosed as papillary thyroid carcinoma with osseous metaplasia and mature bone formation.BACKGROUNDː In Romania, there is no acromegal